Owen A. Ross PhD
Neurology, Biochemistry and Molecular Genetics, Genetics, Neuroscience
Scottsdale, Arizona, United States of America
Connect with the speaker?
Dr. Ross has played an important role in characterizing the two most important genes in Parkinson's disease, LRRK2 and SNCA. He has identified functional common risk factors and patient populations in Parkinson's disease, demonstrating the importance of genetics in sporadic disease. He has also identified novel genes for Parkinson's disease and a number of related disorders.
The research interests of Owen A. Ross, Ph.D., revolve around the area of genetics in aging and age-related disorders. Dr. Ross' primary research is focused on the role of genetics in familial and sporadic forms of parkinsonism and related movement disorders.
Dr. Ross believes individualized medicine will become central in disease treatment with therapeutic intervention based on the genomic background of each patient. Neurogenetic methods may now refine patient diagnosis, identify biomarkers of early and progressive disease, nominate "druggable" targets, establish functional assays for drug development, as well as the in vivo models on which to test them. Neurogenetics laboratories conceptualize the theme of a bench-to-bedside approach and represent translational neuroscience in practice.
His publications are as follows:
Frontotemporal dementia-associated N279K tau mutant disrupts subcellular vesicle trafficking and induces cellular stress in iPSC-derived neural stem cells. Wren MC, Zhao J, Liu CC, Murray ME, Atagi Y, Davis MD, Fu Y, Okano HJ, Ogaki K, Strongosky AJ, Tacik P, Rademakers R, Ross OA, Dickson DW, Wszolek ZK, Kanekiyo T, Bu G. Mol Neurodegener. 2015 Sep 15;10(1):46. doi: 10.1186/s13024-015-0042-7. PMID: 26373282.
Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. Wang L, Aasly JO, Annesi G, Bardien S, Bozi M, Brice A, Carr J, Chung SJ, Clarke C, Crosiers D, Deutschländer A, Eckstein G, Farrer MJ, Goldwurm S, Garraux G, Hadjigeorgiou GM, Hicks AA, Hattori N, Klein C, Jeon B, Kim YJ, Lesage S, Lin JJ, Lynch T, Lichtner P, Lang AE, Mok V, Jasinska-Myga B, Mellick GD, Morrison KE, Opala G, Pihlstrøm L, Pramstaller PP, Park SS, Quattrone A, Rogaeva E, Ross OA, Stefanis L, Stockton JD, Silburn PA, Theuns J, Tan EK, Tomiyama H, Toft M, Van Broeckhoven C, Uitti RJ, Wirdefeldt K, Wszolek Z, Xiromerisiou G, Yueh KC, Zhao Y, Gasser T, Maraganore DM, Krüger R, Sharma M; GEO-PD Consortium. Neurology. 2015 Sep 9. pii: 10.1212/WNL.0000000000002016. [Epub ahead of print] PMID: 26354989.
Autosomal dominant Parkinson's disease caused by SNCA duplications. Konno T, Ross OA, Puschmann A, Dickson DW, Wszolek ZK. Parkinsonism Relat Disord. 2015 Sep 3. pii: S1353-8020(15)00382-X. doi: 10.1016/j.parkreldis.2015.09.007. [Epub ahead of print] PMID: 26350119.
The research interests of Owen A. Ross, Ph.D., revolve around the area of genetics in aging and age-related disorders. Dr. Ross' primary research is focused on the role of genetics in familial and sporadic forms of parkinsonism and related movement disorders.
Dr. Ross believes individualized medicine will become central in disease treatment with therapeutic intervention based on the genomic background of each patient. Neurogenetic methods may now refine patient diagnosis, identify biomarkers of early and progressive disease, nominate "druggable" targets, establish functional assays for drug development, as well as the in vivo models on which to test them. Neurogenetics laboratories conceptualize the theme of a bench-to-bedside approach and represent translational neuroscience in practice.
His publications are as follows:
Frontotemporal dementia-associated N279K tau mutant disrupts subcellular vesicle trafficking and induces cellular stress in iPSC-derived neural stem cells. Wren MC, Zhao J, Liu CC, Murray ME, Atagi Y, Davis MD, Fu Y, Okano HJ, Ogaki K, Strongosky AJ, Tacik P, Rademakers R, Ross OA, Dickson DW, Wszolek ZK, Kanekiyo T, Bu G. Mol Neurodegener. 2015 Sep 15;10(1):46. doi: 10.1186/s13024-015-0042-7. PMID: 26373282.
Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. Wang L, Aasly JO, Annesi G, Bardien S, Bozi M, Brice A, Carr J, Chung SJ, Clarke C, Crosiers D, Deutschländer A, Eckstein G, Farrer MJ, Goldwurm S, Garraux G, Hadjigeorgiou GM, Hicks AA, Hattori N, Klein C, Jeon B, Kim YJ, Lesage S, Lin JJ, Lynch T, Lichtner P, Lang AE, Mok V, Jasinska-Myga B, Mellick GD, Morrison KE, Opala G, Pihlstrøm L, Pramstaller PP, Park SS, Quattrone A, Rogaeva E, Ross OA, Stefanis L, Stockton JD, Silburn PA, Theuns J, Tan EK, Tomiyama H, Toft M, Van Broeckhoven C, Uitti RJ, Wirdefeldt K, Wszolek Z, Xiromerisiou G, Yueh KC, Zhao Y, Gasser T, Maraganore DM, Krüger R, Sharma M; GEO-PD Consortium. Neurology. 2015 Sep 9. pii: 10.1212/WNL.0000000000002016. [Epub ahead of print] PMID: 26354989.
Autosomal dominant Parkinson's disease caused by SNCA duplications. Konno T, Ross OA, Puschmann A, Dickson DW, Wszolek ZK. Parkinsonism Relat Disord. 2015 Sep 3. pii: S1353-8020(15)00382-X. doi: 10.1016/j.parkreldis.2015.09.007. [Epub ahead of print] PMID: 26350119.
EVENTS & ACTIVITIES (Speaking, Spoken, and Authored)
Quick Links
- 50 Division Street, Suite 501,
- Somerville, NJ 08876
- support@emedevents.com